A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Evaluate the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) as Monotherapy or in Combination with Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects with Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma is a fast-growing cancer of the immune system. The usual first treatment relies on a powerful type of chemotherapy called anthracyclines. However, these drugs can place heavy strain on the heart, meaning some people cannot safely receive them because of existing heart issues, age, or general health. This phase 2 trial tests an alternative approach using a targeted drug called epcoritamab. Epcoritamab is an antibody designed to guide your body's own immune cells to attack the cancer cells. Participants receive epcoritamab either on its own or together with another cancer medicine called lenalidomide. The main aim of the trial is to see if this treatment can clear all signs of lymphoma (called a complete response). Doctors will also measure how long the response lasts, monitor any side effects, and check how the treatment affects everyday quality of life.
At a glance
What is this study about?
Diffuse large B-cell lymphoma (often called DLBCL) is a type of blood cancer affecting white blood cells in your lymphatic system. For most people, the first step in care is a combination of chemotherapy drugs that includes anthracyclines. While effective, anthracyclines are tough on the heart. For older adults or anyone with pre-existing heart conditions, standard chemotherapy may carry too high a risk.
This clinical study explores a gentler, more targeted way to treat DLBCL without using anthracyclines. The main drug being tested is epcoritamab. It works like a bridge: one end latches onto cancer cells, and the other end grabs your own immune cells (T cells). This brings the immune cells close enough to recognise and destroy the cancer cells. Researchers want to find out whether giving epcoritamab alone, or alongside a pill called lenalidomide, can successfully treat the cancer from the start.
Because this is a phase 2 trial, doctors are looking closely at how well the treatment shrinks or clears the cancer. They are also tracking side effects, symptom relief, and daily well-being using patient questionnaires. Finding effective first-line options for people who cannot have standard chemotherapy is vital for improving cancer care and offering hope to those with fewer treatment choices.
Key takeaways
- Tests a targeted immune therapy for diffuse large B-cell lymphoma.
- Aims to help people who cannot safely receive standard, heart-straining chemotherapy.
- Compares epcoritamab given alone against epcoritamab combined with lenalidomide.
- Given as an injection under the skin rather than a long chemotherapy drip.
- Taking part is completely voluntary and you can withdraw at any time.
Who may be eligible?
This trial is designed for people who have been diagnosed with diffuse large B-cell lymphoma and have not yet received treatment for it.
To be considered, your doctor must have determined that standard chemotherapy containing anthracyclines is not safe for you. This is usually because of heart health, kidney health, age, or other physical conditions that make intense chemotherapy too risky.
Both men and women may be able to join. Your hospital doctor will carry out detailed blood tests, heart checks, and scans to ensure it is safe for you to take part before any treatment begins.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- I have not yet started any treatment for my lymphoma.
- My medical team has advised that standard anthracycline chemotherapy is unsuitable for me.
- I am able and willing to attend regular hospital appointments for injections, scans, and blood tests.
What does participation involve?
Taking part involves regular visits to a specialist hospital or cancer clinic. Epcoritamab is given as an injection just under the skin. If you also receive lenalidomide, this comes as capsules taken by mouth. Before treatment, you will be given simple medicines such as paracetamol, allergy tablets, or steroids to help prevent mild reactions.
During the trial, your healthcare team will monitor you closely with blood tests, physical checks, and imaging scans (such as PET or CT scans) to see how the lymphoma is responding. You will also be asked to fill out short questionnaires about your symptoms and daily quality of life. The treatment lasts for several months, followed by regular check-ups to track your health over the long term.
Potential risks and benefits
Locations (8)
- —UnverifiedBelgium
- —UnverifiedCzechia
- —UnverifiedFrance
- —UnverifiedGermany
- —UnverifiedAustria
- —UnverifiedPoland
- —UnverifiedItaly
- —UnverifiedSpain
Common questions
What does 'anthracycline-ineligible' mean?
Anthracyclines are strong chemotherapy drugs that can strain the heart. 'Ineligible' simply means your doctors feel these drugs are not safe for you, often due to heart conditions, age, or other health concerns.
Will I receive a dummy drug (placebo)?
No. This is an open-label study, meaning every participant receives active cancer medication. You will receive either epcoritamab alone or epcoritamab combined with lenalidomide.
How is epcoritamab given?
Epcoritamab is given as an injection under the skin (subcutaneously), similar to how insulin or some blood thinners are given, rather than through a long intravenous drip.
What extra medications will I need to take?
You will receive common medicines like paracetamol, antihistamines, and steroids shortly before treatment to prevent allergic reactions and fever.
What happens if I decide to leave the trial?
You can leave the study at any point. Your medical team will discuss other suitable treatment options with you, and your standard NHS care will continue as normal.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.